logo

WOCKPHARMA vs ZIMLAB: Stock Comparison

WOCKHARDT vs ZIM LABORATORIESUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

WOCKHARDT is the larger company by market capitalisation. WOCKHARDT shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

WOCKPHARMA leads 9; ZIMLAB leads 1 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

WOCKPHARMAZIMLAB

Valuation lens

What price are you paying?

Market CapContext only
₹30,126 Cr
₹720 Cr
P/E RatioWOCKPHARMA has the lower reading
73.66x ✓
182.5x
P/B RatioZIMLAB has the lower reading
6.1x
2.51x ✓
EPSWOCKPHARMA has the higher reading
₹6.52 ✓
₹-0.75
Book ValueContext only
₹325
₹55.31
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹30,126 Cr vs ₹720 Cr
P/E Ratio
WOCKPHARMA has a lower P/E
73.66x vs 182.5x
P/B Ratio
ZIMLAB has a lower P/B
2.51x vs 6.1x
EPS
WOCKPHARMA has higher earnings per share
₹6.52 vs ₹-0.75
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs -3.36%
EPS Growth (TTM YoY)
WOCKPHARMA has faster EPS growth
0% vs -47.01%
ROE
WOCKPHARMA has a higher ROE
3.77% vs 1.97%
ROCE
WOCKPHARMA has a higher ROCE
5.44% vs 3.86%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricWOCKPHARMAZIMLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricWOCKPHARMAZIMLAB
Live Price₹1,855.5₹132.12
Day Change-1.16%-0.13%
Volume4.57 L73,408
52-Week High₹2,422.3₹159.81
52-Week Low₹1,086.7₹59.31
Distance from 52W High-23.4%-17.33%

Valuation

MetricWOCKPHARMAZIMLAB
Market Cap₹30,126 Cr₹720 Cr
P/E Ratio73.66x182.5x
P/B Ratio6.1x2.51x
EPS₹6.52₹-0.75
Book Value₹325₹55.31
Dividend Yield0%0%

Growth

MetricWOCKPHARMAZIMLAB
Revenue Growth (TTM YoY)26%-3.36%
EPS Growth (TTM YoY)0%-47.01%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricWOCKPHARMAZIMLAB
ROE3.77%1.97%
ROCE5.44%3.86%
Net Margin3.3%1.56%
Operating Margin13.37%5.72%
Debt to Equity0.4x0.42x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricWOCKPHARMAZIMLAB
Promoter Holding49.08%30.3%▼ 0.06 pp
FII Holding7.22%▲ 0.13 pp0.17%▲ 0.14 pp
DII Holding9.24%▼ 1.72 pp1.19%▼ 0.14 pp
Public Holding34.44%▲ 1.61 pp68.34%▲ 0.06 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: WOCKHARDT and ZIM LABORATORIES.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.